Rational design of antituberculosis vaccines: Impact of antigen display and vaccine localization

Biologicals

Volumn 25, Issue 2, 1997, Pages 169-173

  Kaufmann, Stefan H E ^a,b   Hess, Jürgen ^a,b  

^a UNIVERSITY OF ULM   (Germany)

^b MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

CONFERENCE PAPER; DRUG DESIGN; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; TUBERCULOSIS;

MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS;

EID: 0031171815     PISSN: 10451056     EISSN: None     Source Type: Journal    
DOI: 10.1006/biol.1997.0079     Document Type: Conference Paper

References (25)

1. 1. Stead WW, Dutt AK. Changing faces of clinical tuberculosis. In: Bendinelli M, Friedman, H, eds, Mycobacterium tuberculosis: Interactions with the immune system. New York: Plenum Press, 1988; 371-387.
2. 2. Huebner RE. BCG vaccination in the control of tuberculosis. In: Shinnick TM, ed., Curr Top Microbiol Immunol: Tuberculosis. Berlin: Springer, 1996; 263-279.
3. 3. Colditz GA et al. Efficacy of BCG vaccine in the prevention of tuberculosis. J Am Med Assoc 1994; 271: 698-702.
4. 4. Dooley SW, Simone M. The extent and management of drug-resistant tuberculosis: the American experience. In: Davies PDO, ed., Clinical Tuberculosis. London: Chapman & Hall, 1994; 171-189.
5. 5. Grange JM. Epidemiological aspects of drug resistance. In: Mycobacteria and Human Disease. London: Arnold, 1996; 124-125.
6. 6. Smith PG, Moss AR. Epidemiology of tuberculosis. In: Bloom BR, ed., Tuberculosis: Pathogenesis, protection, and control. Washington, DC: ASM Press, 1994; 47-59.
7. 7. Kaufmann SHE. Tuberculosis: The role of the immune response. The Immunologist 1993; 1/4: 109-114.
8. 8. Flynn, JL et al. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc Natl Acad Sci USA 1992; 89: 12013-12017.
9. 9. Kaufmann SHE. γ/δ and other unconventional T lymphocytes: What do they see and what do they do? Proc Natl Acad Sci USA 1996; 93: 2272-2279.
10. 10. Tanaka Y, Morita CT et al. Natural and synthetic non-peptide antigens recognized by human γδ T cells. Nature 1995; 375: 155-158.
11. 11. Kato K, Yamamoto K-I. Role of adjuvant and immunogenie moieties of M. tuberculosis in pathogenicity. In: Bendinelli M, Friedman H, eds, Mycobacterium tuberculosis: Interactions with the Immune System. New York: Plenum Press, 1988; 39-58.
12. 12. Mahairas GG, Sabo PJ, Hickey MJ et al. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J Bacteriol 1996; 178: 1274-1282.
13. 13. Sorensen AL, Nagai S, Houen G, Andersen P, Andersen AB. Purification and characterization of a low-molecular-mass-T-cell antigen secreted by Mycobacterium tuberculosis. Infect Immun 1995; 63: 1710-1717.
14. 14. Harboe M, Oettinger T, Wiker HG et al. Evidence for occurrence of the ESAT-6 protein in Mycobacterium tuberculosis and virulent Mycobacterium bovis and for its absence in Mycobacterium bovis BCG. Infect Immun 1996; 64: 16-22.
15. 15. Andersen P, Andersen AB, Sorensen AL, Nagai S. Recall of long-lived immunity to Mycobacterium tuberculosis infection in mice. J Immunol 1995; 154: 3359-3372.
16. 16. Hess J, Kaufmann SHE. Vaccination strategies against intracellular microbes. FEMS Immunol Med Microbiol 1993; 7: 95-104.
17. 17. Hormaeche CE, Khan CMA. Recombinant bacteria as vaccine carriers of heterologous antigens. In: Kaufmann SHE, ed., Concepts in Vaccine Development. Berlin: Walter de Gruyter, 1996; 327-349.
18. 18. Stover CK. Recombinant vaccine delivery systems and encoded vaccines. Curr Opin Immunol 1994; 6: 568-571.
19. 19. Hess J, Gentschev I, Miko D, Welzel M, Ladel CH, Goebel W, Kaufmann SHE. Superior efficacy of secreted over somatic p60 or listeriolysin antigen display in recombinant Salmonella vaccine induced protection against listeriosis. Proc Natl Acad Sci USA 1996; 93: 1458-1463.
20. 20. Horwitz MA, Lee B-WE, Dillon BJ et al. Protective immunity against tuberculosis induced by vaccination with major extracellular proteins against Mycobacterium tuberculosis. Proc Natl Acad Sci USA 1995; 92: 1530-1534.
21. 21. Andersen P. Effective vaccination of mice against Mycobacterium tuberculosis infection with soluble mixture of secreted mycobacterial proteins. Infect Immun 1994; 62: 2536-2544.
22. 22. Roberts AD, Sonnenberg MG, Ordway DJ et al. Characteristics of protective immunity engendered by vaccination of mice with purified culture filtrate antigens of Mycobacterium tuberculosis. Immunology 1995; 85: 502-508.
23. 23. Huygen K, Content J, Denis O, Montgomery DL et al. Immunogenicity and protective efficacy of tuberculosis DNA vaccine. Nature Med 1996; 2: 893-898.
24. 24. Tascon RE, Colston MJ, Ragno S et al. Vaccination against tuberculosis by DNA injection. Nature Med 1996; 2: 888-892.
25. 25. Reyrat JM, Berthet FX, Gicquel B. The urease locus of Mycobacterium tuberculosis and its utilization for the demonstration of allelic exchange in Mycobacterium bovis bacillus Calmette-Guérin. Proc Natl Acad Sci USA 1995; 92: 8768-8772.